|1.||Magelli, Merrell: 3 articles (07/2011 - 01/2011)|
|2.||Lionberger, David R: 3 articles (01/2011 - 01/2010)|
|3.||Rovati, S: 2 articles (08/2011 - 08/2010)|
|4.||Magelli, M: 2 articles (08/2011 - 08/2010)|
|5.||Yanchick, J: 2 articles (08/2011 - 08/2010)|
|6.||Yanchick, Jillmarie: 2 articles (01/2011 - 01/2011)|
|7.||Joussellin, Eric: 2 articles (01/2011 - 01/2011)|
|8.||Lanzarotti, Arturo: 2 articles (01/2011 - 01/2011)|
|9.||Dadapeer, Echchukattula: 1 article (01/2014)|
|10.||Vorčáková, Katarína: 1 article (01/2014)|
02/01/2011 - "In this exploratory study, patients experienced well-tolerated relief for acute pain due to back strain, with ≥ 85% of patients and their investigators expressing satisfaction with DETP treatment."
02/01/2011 - "This exploratory, multicenter, open-label study evaluated effectiveness and safety of DETP in patients with acute pain due to back strain. "
06/01/2010 - "Primary analyses among the 8 studies reported DETP-associated reductions in spontaneous pain from baseline, assessed using a visual analog scale, ranging from 26% to 88% on day 7 and 56% to 61% on day 14. "
02/01/2011 - "At baseline, patients with an average pain intensity of ≥ 4 started DETP treatment (q12h). "
01/01/2011 - "Beginning approximately 3 hours after initial treatment, DETP-treated patients experienced statistically significant and sustained lower mean VAS scores in pain intensity on movement (mean ± SD, 54.1 ± 20.0 mm versus 60.3 ± 16.8 mm) compared with placebo-treated patients, representing a 20% versus 13% reduction in VA S pain scores from baseline (P = 0.012). "
|2.||Sprains and Strains (Sprain)
08/01/2010 - "Data from two double-blind, randomized, parallel-group, placebo-controlled studies (N = 274) of safety and efficacy of the DETP applied once daily for 7 days for acute ankle sprain were evaluated post-hoc using statistical modeling to estimate time to onset of significant pain reduction following DETP application. "
01/01/2011 - "Overall, the results of this study demonstrate that the DETP is an effective analgesic for local treatment of pain in mild acute ankle sprain."
08/01/2010 - "This retrospective post-hoc analysis examined time to onset of significant pain reduction after DETP application compared to a placebo patch for patients with mild-to-moderate acute ankle sprain, evaluating the primary efficacy endpoint from two nearly identical studies. "
01/01/2011 - "These results further confirm the efficacy and safety of DETP for the treatment of acute pain from ankle sprains. "
01/01/2011 - "The present study assessed the efficacy and safety of the diclofenac epolamine topical patch (DETP, 1.3%), a topical NSAID for the treatment of acute minor sprains and strains. "
|3.||Soft Tissue Injuries (Soft Tissue Injury)
06/01/2010 - "The search identified 6 placebo-controlled clinical studies, 1 active-comparator-controlled clinical study, and 1 open-label comparator clinical study of the efficacy and tolerability of the DETP in patients with soft tissue injuries. "
08/01/2010 - "The DETP is an effective treatment for acute minor soft tissue injury, providing pain relief as rapidly as 1.27 hours post-treatment. "
06/01/2010 - "Based on data from clinical studies and postmarketing experience, the DETP was associated with significant pain relief in patients with soft tissue injuries, with good tolerability."
06/01/2010 - "Clinical studies of the efficacy and/or tolerability of the DETP in patients with acute pain due to soft tissue injuries or localized periarticular disorders were included. "
06/01/2010 - "The aim of this study was to review the efficacy and tolerability of the DETP in relieving acute pain caused by soft tissue injuries. "
|4.||Ankle Injuries (Ankle Injury)
01/01/2011 - "Pain intensity was evaluated during the first six hours after application of the patch, and on treatment days 1, 2, 3, and 7. Patients treated with the DETP experienced a significantly greater reduction in pain associated with their ankle injury compared with placebo, beginning four hours after the first patch application (P = 0.02). "
|5.||Body Weight (Weight, Body)
07/31/2007 - "Groups of rats were orally administered CPF, DEP, TCPy or DETP at doses of 140mumol/kg body weight, and the time-courses of the metabolites were evaluated in blood and urine. "
05/01/2007 - "To assess the effect of coumaphos [O-(3-chloro-4-methyl-2-oxo-2H-1-benzopyran-7-yl) O,O-diethyl phosphorothioate] exposure on physiological responses during bovine production, acetylcolinesterase (AChE) and butyrylcholinesterase (BuChE) activities were measured in whole blood, erythrocytes, and plasma of healthy male steers (Bos Taurus x Bos indicus) sprayed with coumaphos at a non-lethal dose of 1 mg kg(- 1) body weight per day once every 14 (in vivo group) or 21 days (southern and central groups). "
08/05/2002 - "This study gave oral (11 microg kg(-1) (36 nmol kg(-1)) body weight) and occluded dermal (100 mg (329 micromol)) doses of diazinon to five volunteers and analysed blood and urine samples for plasma and erythrocyte cholinesterase and urinary dialkyl phosphate (DAP) metabolites of diazinon: diethyl phosphate (DEP) and diethyl thiophosphate (DETP). "
|1.||Diclofenac (SR 38)
|2.||diclofenac hydroxyethylpyrrolidine (DIEP)
|3.||Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
|4.||1-(2-(dodecyloxy)ethyl)pyrrolidine hydrochloride (DEP)
|7.||thiophosphoric acid (thiophosphate)